An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides

被引:32
作者
Tong, Pei [1 ]
Lu, Zhifeng [1 ]
Chen, Xi [1 ]
Wang, Qian [2 ,3 ,4 ]
Yu, Fei [5 ]
Zou, Peng [5 ]
Yu, Xiaoxia [6 ]
Li, Yu [1 ]
Lu, Lu [2 ,3 ,4 ,5 ]
Chen, Ying-Hua [1 ]
Jiang, Shibo [2 ,3 ,4 ,5 ]
机构
[1] Tsinghua Univ, Sch Life Sci, Key Lab Prot Sci, MOE, Beijing 100084, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, Minist Educ, Shanghai 200032, Peoples R China
[3] Fudan Univ, Shanghai Med Coll, Key Lab Med Mol Virol, Minist Hlth, Shanghai 200032, Peoples R China
[4] Fudan Univ, Inst Med Microbiol, Shanghai 200032, Peoples R China
[5] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA
[6] Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China
基金
中国国家自然科学基金;
关键词
N-heptad repeat; trimer; disulphide bonds; enfuvirtide; tenofovir; DRUG-RESISTANT HIV-1; FUSION INHIBITOR; PRECLINICAL EVALUATION; SEXUAL TRANSMISSION; PEPTIDE INHIBITOR; ESCHERICHIA-COLI; HIGHLY POTENT; ENFUVIRTIDE; DESIGN; ENTRY;
D O I
10.1093/jac/dkt230
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: We previously constructed a trimeric coiled coil, N28Fd, based on the N-heptad repeat (NHR) sequence of HIV-1 gp41, as a promising HIV-1 entry inhibitor. Here, we attempted to engineer a stabilized trimeric coiled coil, ccN28Fd, by adding interchain disulphide bonds at the N terminus of N28Fd to improve its biophysical properties and anti-HIV-1 efficacy, Methods: Molecular biology techniques were applied to engineer ccN28Fd. Circular dichroism and sedimentation velocity analysis were used to determine its secondary structure and thermostability and polymeric states, respectively. The anti-HIV-1 activity was assessed by p24 or luciferase expression. Its cytotoxicity was evaluated by XTT assay. Results: At low pH, ccN28Fd and N28Fd were in trimeric and monomeric conformation, respectively. ccN28Fd showed higher thermostability and much stronger antiviral activity against HIV-1 IIIB (X4) and Bal (R5) strains than N28Fd. ccN28Fd was effective in inhibiting infection by a broad spectrum of primary HIV-1 isolates and enfuvirtide-resistant strains and blocking cell-to-cell HIV-1 transmission. A combination of ccN28Fd with tenofovir, a nucleoside reverse transcriptase inhibitor-based microbicide, exhibited potent synergistic anti-HIV-1 activity. ccN28Fd was highly resistant to digestion by proteinase K at pH 7,2 and pepsin at pH 1.5, and its anti-HIV-1 activity was not significantly affected by the presence of hydroxyethyl cellulose gel, seminal fluid or vaginal fluid simulant. It possessed no significant in vitro cytotoxicity. Conclusions: The engineered ccN28Fd maintains high stability in a low pH environment and exhibits potent and broad anti-HIV-1 activity, suggesting good potential for development as an effective and safe vaginal microbicide to prevent HIV sexual transmission.
引用
收藏
页码:2533 / 2544
页数:12
相关论文
共 56 条
[1]  
Abdool KarimQ., 2010, Science, V329, P1168, DOI DOI 10.1126/SCIENCE.1193748
[2]  
[Anonymous], 2013, AIDS epidemic update: November 2009
[3]   Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41 [J].
Bewley, CA ;
Louis, JM ;
Ghirlando, R ;
Clore, GM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (16) :14238-14245
[4]   Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic [J].
Bird, Gregory H. ;
Madani, Navid ;
Perry, Alisa F. ;
Princiotto, Amy M. ;
Supko, Jeffrey G. ;
He, Xiaoying ;
Gavathiotis, Evripidis ;
Sodroski, Joseph G. ;
Walensky, Loren D. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (32) :14093-14098
[5]   No increase in cervicovaginal proinflammatory cytokines after carraguard use in aplacebo-controlled randomized clinical trial [J].
Bollen, Liesbeth J. M. ;
Blanchard, Kelly ;
Kilmarx, Peter H. ;
Chaikummao, Supaporn ;
Connolly, Cathy ;
Wasinrapee, Punneporn ;
Srivirojana, Nucharee ;
Achalapong, Jullapong ;
Tappero, Jordan W. ;
McNicholl, Janet M. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (02) :253-257
[6]   THE BACKBONE STRUCTURE OF THE MAJOR COLD-SHOCK PROTEIN CS7.4 OF ESCHERICHIA-COLI IN SOLUTION INCLUDES EXTENSIVE BETA-SHEET STRUCTURE [J].
CHATTERJEE, S ;
JIANG, WN ;
EMERSON, SD ;
INOUYE, M .
JOURNAL OF BIOCHEMISTRY, 1993, 114 (05) :663-669
[7]   Scientists rethink approach to HIV gels [J].
Check, Erika .
NATURE, 2007, 446 (7131) :12-12
[8]   Novel Recombinant Engineered gp41 N-terminal Heptad Repeat Trimers and Their Potential as Anti-HIV-1 Therapeutics or Microbicides [J].
Chen, Xi ;
Lu, Lu ;
Qi, Zhi ;
Lu, Hong ;
Wang, Ji ;
Yu, Xiaoxia ;
Chen, Yinghua ;
Jiang, Shibo .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (33) :25506-25515
[9]   Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [J].
Chou, Ting-Chao .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :621-681
[10]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560